Joan C Gill
Overview
Explore the profile of Joan C Gill including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
266
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ellery P, Hilden I, Thyregod P, Martinez N, Maroney S, Gill J, et al.
Haemophilia
. 2019 Oct;
25(6):1083-1091.
PMID: 31608540
Introduction: Tissue factor pathway inhibitor (TFPI) is a naturally occurring anticoagulant found in plasma, where it circulates bound to lipoproteins, factor V (FV) or Protein S (PS), and in platelets....
2.
Gill J, Roberts J, Li Y, Castaman G
Haemophilia
. 2019 Mar;
25(3):e219-e222.
PMID: 30866086
No abstract available.
3.
Marek E, Momper J, Hines R, Takao C, Gill J, Pravica V, et al.
J Pediatr Pharmacol Ther
. 2016 Jul;
21(3):224-32.
PMID: 27453700
Objectives: The objective of this study was to evaluate the performance of pediatric pharmacogenetic-based dose prediction models by using an independent cohort of pediatric patients from a multicenter trial. Methods:...
4.
Mahlangu J, Kuliczkowski K, Karim F, Stasyshyn O, Kosinova M, Lepatan L, et al.
Blood
. 2016 Jun;
128(5):630-7.
PMID: 27330001
Recombinant VIII (rVIII)-SingleChain is a novel B-domain-truncated recombinant factor VIII (rFVIII), comprised of covalently bonded factor VIII (FVIII) heavy and light chains. It was designed to have a higher binding...
5.
Gill J, Castaman G, Windyga J, Kouides P, Ragni M, Leebeek F, et al.
Blood
. 2015 Aug;
126(17):2038-46.
PMID: 26239086
This phase 3 trial evaluated the safety and hemostatic efficacy of a recombinant von Willebrand factor (rVWF) for treatment of bleeds in severe von Willebrand disease (VWD). rVWF was initially...
6.
Niebler R, Gill J, Brabant C, Mitchell M, Nugent M, Simpson P, et al.
World J Pediatr Congenit Heart Surg
. 2013 Jun;
3(4):433-8.
PMID: 23804904
Background: Perioperative bleeding is common in pediatric cardiac surgery patients. Traditional laboratory tests do not adequately characterize coagulation derangements in patients with bleeding. We sought to establish preoperative thromboelastography parameters...
7.
Gupta S, Siddiqi A, Soucie J, Manco-Johnson M, Kulkarni R, Lane H, et al.
Br J Haematol
. 2013 Feb;
161(3):424-33.
PMID: 23432684
This study prospectively compared the effect of secondary prophylaxis to episodic treatment on target joint (TJ) range of motion (ROM), number of joint haemorrhages and new TJ development in patients...
8.
Kessler C, Friedman K, Schwartz B, Gill J, Powell J
Thromb Haemost
. 2011 Jul;
106(2):279-88.
PMID: 21725579
The pharmacokinetic (PK) profiles of von Willebrand factor (VWF) /factor VIII (FVIII) concentrates are important for treatment efficacy and safety of von Willebrand disease (VWD) patients. This prospective, head-to-head, randomised...
9.
Cusick M, Yang M, Gill J, Eckels D
Hum Immunol
. 2011 Mar;
72(5):379-85.
PMID: 21377503
Hepatitis C virus (HCV) has a high rate of replication and lacks RNA-proofreading capabilities, thereby leading to variant or mutant viruses circulating within the host as a quasispecies. Previous work...
10.
Cusick M, Schiller J, Gill J, Eckels D
Clin Dev Immunol
. 2011 Jan;
2011:806061.
PMID: 21197453
Regulatory T cell markers are increased in chronically infected individuals with the hepatitis C virus (HCV), but to date, the induction and maintenance of Tregs in HCV infection has not...